Clinical Trial Update: Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the effectiveness of SOX as second-line chemotherapy in neuroendocrine carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• SOX (SOX)

Snippet

Sponsor: Peking University | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: UNKNOWN